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ABSTRACT: A number of diazepines are known to inhibit bromo- and extra-terminal domain (BET) proteins. Their BET inhibito-
ry activity derives from the fusion of an acetyl-lysine mimetic heterocycle onto the diazepine framework. Herein we describe a 
straightforward, modular synthesis of novel 1,2,3-triazolobenzodiazepines and show that the 1,2,3-triazole acts as an effective ace-
tyl-lysine mimetic heterocycle. Structure-based optimization of this series of compounds led to the development of potent BET 
bromodomain inhibitors with excellent activity against AF9-MLL-driven leukemic cells, concomitant with a reduction in c-MYC 
expression. These novel benzodiazepines therefore represent a promising class of therapeutic BET inhibitors.
The bromo- and extra-terminal domain (BET) family of 
proteins are epigenetic reader proteins involved in 
transcription regulation and chromatin remodelling.
1,2
 The 
family consists of BRD2, BRD3 and BRD4, which are 
ubiquitously expressed, and BRDT, which is expressed only in 
the testes. Each BET protein contains two bromodomain 
structural motifs, here designated as D1 and D2, which have 
been shown to bind acetylated lysines on histones H3 and H4, 
and existing data indicates that the biology of BET proteins is 
largely regulated through the first bromodomain.
3,4
 The 
acetylated histone lysine residues bind into a hydrophobic 
pocket of the BET proteins making specific hydrogen bonding 
interactions with a conserved asparagine and tyrosine residue, 
the latter through a water molecule.
5
 In the last six years a 
number of research teams have identified high affinity, small 
molecule ligands for this hydrophobic pocket that block 
binding to the cognate acetylated histones.
6–10
 Such small 
molecule BET inhibitors, along with genetic deletion studies, 
have demonstrated that inhibition of the BET – histone 
interaction can result in profound disruption of transcriptional 
programs resulting in anticancer and anti-inflammatory 
activity, amongst others. For example, treatment of cancer 
cells dependent on the oncogene c-MYC with BET inhibitors, 
either in vitro or in vivo, can result in significant anti-
proliferative and cytotoxic effects. As a consequence of these 
and other data, at least ten BET inhibitors have now entered 
clinical trials for the treatment of a range of hematological 
cancers (incl. leukemia, lymphoma and myeloma), certain 
solid tumors (including glioblastoma multiforme and NUT-
midline carcinoma) and atherosclerosis.
2,11
  
The first potent BET inhibitors described in the literature were 
the benzodiazepine IBET-762 (1)
12,13
 and the related 
thienodiazepine (S)-JQ-1 (2) (Chart 1).
14
 Co-crystal structures 
of these compounds with BRD4(D1) revealed that the 1,2,4-
triazole within these inhibitors acts as an acetyl-lysine mimic 
by interacting with Asn140 and a conserved water molecule in 
the KAc recognition pocket. Constellation Pharmaceuticals 
have reported isoxazole azepines (e.g. 3)
15
 and 
benzotriazolo[4,3-d][1,4]diazepine 4
16
 that also inhibit BET 
bromodomains, while Knapp and coworkers reported that 
benzotriazepine 5 binds to BRD4.
17
 Interestingly, based on 
structural similarities to IBET-762, a range of benzodiazepine 
drugs were retrospectively tested for inhibition of BRD4(D1). 
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 Of these, alprazolam (6) was found to be a weak inhibitor (Kd 
= 2.5 µM) and X-ray crystallography confirmed the 1,2,4-
triazole acts as an acetyl lysine mimetic. Other closely related 
analogues of alprazolam that were devoid of the 1,2,4-triazole 
motif were found to be inactive,
17
 underscoring the importance 
of the acetyl lysine mimicking heterocycle for BET activity. 
We have been interested in understanding the impact of the 
KAc mimicking pharmacophore on bromodomain inhibition. 
Based on previous studies
18
 we designed and tested 
compounds based on a 5H-benzo[f][1,2,3]triazolo[1,5-
d][1,4]diazepine nucleus. The 1,2,3-triazole motif was 
predicted to have appropriate hydrogen-bond accepting vector 
at N2 to interact with the conserved asparagine [Asn140 in 
BRD4(D1)] and molecular modeling indicated that a phenyl 
substituent at N7 of the diazepine ring would project into the 
WPF shelf, closely mapping over chlorophenyl (C6) of 3H-
benzo-1,4-diazepines JQ-1 and IBET-762. We found that this 
is an excellent BET bromodomain-binding framework and, 
through subsequent structure-based optimization, developed a 
series of 1,2,3-triazolobenzodiazepines that display potent 
BET bromodomain inhibition and excellent cellular activity. 
 
 
 
 
 
 
 
 
 
 
Initially, we prepared 1,2,3-triazole-containing benzodiazepine  
7 via the route shown in Scheme 1. Starting from 1,2-
diiodobenzene (8), Buchwald coupling with aniline afforded 
diarylaniline 9. The propyne was introduced at the remaining 
iodinated position using Sonogashira cross-coupling and the 
product (10) was acetylated with chloroacetyl chloride 
providing chloroacetamide 11. Based on a report by Majumdar 
et. al. and others,
19-21
 we performed a one-pot SN2/Hüigsen 
1,3-dipolar cycloaddition reaction cascade to directly prepare 
the 1,2,3-triazolobenzodiazepine framework by heating 11 to 
150 
o
C in the presence of sodium azide. While this strategy 
provided triazole 12 as expected, the un-optimized yield in this 
case was low (13%). Nevertheless, with the diazepinone in 
hand, selective deletion of the carbonyl oxygen with borane 
provided the desired 1,2,3-triazolobenzodiazepine 7. Using an 
optimized version of this general strategy, followed by 
additional late-stage cross-coupling reactions and other 
functional group interconversions, we synthesized a range of 
analogs shown in Table 1 (see electronic supporting 
information for full synthetic details). 
 
 
 
 
 
 
 
 
Initially we assessed the BET inhibitory activity of 7 using 
AlphaScreen
TM
, a well-validated competition binding assay. 
Gratifyingly, 7 showed good activity in this assay against all 
bromodomains tested with the strongest activity against 
BRD4(D2) (IC50 = 22 nM), but significantly weaker activity 
against BRD2(D1) (IC50 = 264 nM) (Figure 1 and Table 1). 
Control compound, JQ-1, gave BRD4(D2) IC50 = 12 nM and 
BRD2(D1) IC50 = 26 nM (Figure 1). We also tested the 
diazepinone (12) but this was essentially inactive (IC50 greater 
than 10 µM, data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Synthesis of 1,2,3-triazolobenzodiazepines: 
Synthesis of 7.  
Figure 1. Dose response plots for AlphaScreen
TM
 assays. 
Results of at least 2 independent experiments reported as 
mean ± SD. 
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 The good ligand efficiency [0.51 kcal.mol
-1
 per non-hydrogen 
atom for BRD4(D2)] of 7 prompted us to expand this series 
and explore structure-activity relationships with the view to 
improve the overall BET activity. First we briefly examined 
modifications to the D-ring. Benzyl substitution at  N7 (13) 
led to a reduction in activity by greater than 50-fold against all 
bromodomains tested, while addition of either meta or para 
substituents on the D-ring were tolerated in terms of overall 
activity with the 4-chlorophenyl-substituted analog 15 
provided a modest improvement over the activity of parent 
compound 7 [about 2-fold improvement against BRD2(D1)], 
consistent with previous studies on BET inhibitors, and we 
therefore retained this modification in subsequent compounds. 
Next we investigated modifications to the A-ring. Crystal 
structures of both IBET-762 (pdb code 2YEK) or alprazolam 
(pdb code 3U5J) bound to BET bromodomains indicated that 
substitution at C9 (C8 in IBET-762 numbering) projected into 
the ZA channel and we extrapolated that our series of 
benzodiazepines would also accommodate functionalization at 
this position.  A set of compounds was therefore designed to 
incorporate a substituent from the C9 vector. From the activity 
of the set of C9 analogs it was clear that sp
3
 substitution 
provided no improvement in activity (compounds 16, 17 and 
27), whereas heteroaryl substituents significantly improved 
activity, with pyrazole 18 and aminopyridine 20 giving IC50 
values as low as 7 and 6 nM respectively against BRD4(D2). 
Interestingly, tetrazole 22 showed the greatest activity across 
each bromodomain with IC50 values ranging from 7 nM 
against BRD2(D2) to 2 nM against BRD4(D2). At this point 
we established the binding mode of the aminopyridyl-
substituted compound (20) in BRD2(D2) by single crystal X-
ray analysis (Figure 2). The structure confirmed that the 1,2,3-
triazole motif acts as an acetyl-lysine mimetic, accepting a 
hydrogen bond from both Asn429 and the conserved water 
molecule coordinated to Tyr386, as expected. Additionally, 
the chlorophenyl ring lies within the WPF shelf and the 
aminopyridine ring extends through the ZA channel and 
towards solvent exposed space. The positioning of the 
aminopyridine towards solvent indicated that modifications to 
this position should be well tolerated. Based on these 
structural insights we reasoned that other sp
2
-hybridized 
moities, such as carbonyls, might also improve potency and 
allow for greater diversity of functionalization. Initially we 
compared carboxylic acids, esters and simple amides. In 
general, these derivatives showed good activity. Of the initial 
carbonyl series, primary amide 25 was significantly more 
potent (~3-fold) against all BET bromodomains tested 
compared with ester 23 and prompted us to explore the amide 
derivatives further. The benzyl amide series (compounds 29 to 
33) were also exceptionally potent, particularly chiral benzyl 
amides 29, 30 and 31. Further, in the amide series the S-
configured amides 29 and 30 displayed significant domain 
selectivity [BRD2(D2) vs BRD2(D1)] realtive to the R-
configured analog 31. In light of the potent activity of the 
tetrazole, 22, we explored bioisosteric acylsulfonamides at the 
C9 position. These compounds, although somewhat less active 
than the tetrazole, also displayed low nanomolar activity 
against BRD4(D2) despite the significantly increased steric 
bulk, further attesting to the accomodation of sp
2
-
modifications at C9. Lastly, we investigated substitutions to 
the benzodiazepine ring. Methyl substitution at C5 
(Compounds 36, 37) improved activity against BRD4(D1) and 
the R-stereogenic configuration was preferred consistent with 
similar modification of previously reported benzodiazepine 
BET inhibitors.
16
 
From this chemical series we selected compounds 18 and 20 
for further study because they displayed potent activity and 
were predicted to have good cell permeability (for example the 
tetrazole 22, while potent, is likely an efflux transporter 
substrate).
22
 First, we assessed the bromodomain selectivity of 
20 across a panel of 32 recombinant human bromodomains in 
a bromoMAX
TM
 assay (see electronic supporting information 
for full data). In these assays, 20 showed excellent selectivity 
for the BET family bromodomains. We also assessed the 
binding kinetics of 20 against individual bromodomains using 
surface plasmon resonance (SPR). The dissociation-rate 
measured for compound 20 against BRD2 was approximately 
3-fold slower for domain 2 than domain 1 (kd = 0.039 s
-1
 vs kd 
= 0.13 s
-1
, respectively), whereas association rates were similar 
(ka = 2.90 x10
5
 M
-1
s
-1
 vs  ka = 2.62 x10
5
 M
-1
s
-1
, respectively) 
(see electronic supporting information for full data). 
 
 
 
 
 
 
 
 
 
 
BET inhibition has been shown to have a remarkable effect on 
certain primary cancer cells and cell lines, which is thought to 
be a consequence of downregulation of oncogenes c-MYC, 
BCL-2 and others by displacement of BRD4 from 
hyperacetylated histone tails near their respective promoters 
and enhancers.
23,24
 To test the anti-leukemic effect of this 
chemical series we profiled 18 and 20 against a cancer cell 
panel (Table 2). Compound 20 potently inhibited proliferation 
of known BRD4-dependant leukemic line MLL-AF9, and 
showed significant inhibition of leukemic macrophage cell 
line MV4-11, (EC50 = 140 nM), whereas B cell lymphoma 
lines DOHH2, SU-DHL-4 and Raji, and myeloma cell line 
RPMI-8226 were less sensitive (EC50 > 500 nM). Consistent 
with BET-targeted anti-proliferative effects, BCR-Abl-driven 
cell line K562 was completely resistant to 20 (>1000 nM).  
 
WPF shelf 
ZA channel 
Asn429 
Figure 2. A X-ray crystal structure of 20 (magenta) in 
complex with BRD2(D2) PDB code = 5U6V overlayed 
with co-crystal structure of JQ-1 (grey) bound to 
BRD2(D2) PDB = 3ONI.  
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Table 1. Inhibition of BET bromodomains as determined by AlphaScreen
TM
 assays. Numbers represent mean IC50 in nanomolar 
(nM) of at least two independent experiments. A.  D-ring modifications. B C9 sp3 functionalized derivatives. C C9 sp2-
functionalized derivatives. D C9 carbonyl derivatives. E miscellaneous C9 derivatives. F C9 benzylamide derivatives. G 
Acylsulphonamides. H C5 Alkyl derivatives. 
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domain 1 
domain 2 
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129 25 35 
43 32 
129 21 29 
44 17 
6 3 
7 2 
35 10 14 
25 7 
64 14 23 
38 12 
33 9 13 
21 6 
53 10 16 
28 7 
273 52 45 
147 38 
116 18 29 
52 18 
185 16 28 
50 17 
388 36 79 
40 30 
204 43 
370 23 
56 11 
24 13 
34 6 
17 2 
95 23 34 
4 17 
51 12 10 
3 6 
68 13 14 
20 13 
44 13 
25 7 
151 39 44 
44 14 
136 21 35 
37 15 
79 14 21 
18 13 
54 21 21 
25 10 
53 13 15 
34 10 
38 11 14 
25 7 
340 44 52 
45 36 
>999 >999 
>999 >999 
A B 
C 
D E 
F 
G H 
7 13 14 15 16 17 
18 19 20 21 22 
23 24 25 26 27 28 
29 30 31 32 33 
34 35 36 37 38 
 IC50  
(nM)  
264 19 28 
39 12 
A B 
C 
D 
N7 
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 Osteosarcoma (OS) cells are also known to be sensitive to 
BET inhibition, but through a MYC-independent 
mechanism.
25
 We were therefore interested to characterize the 
effect of 18 and 20 on primary mouse OS cells (fibroblastic 
494H and osteoblastic 148I). Both compounds 18 and 20 
inhibited proliferation of both primary OS cell types, serving 
to highlight the broad utility of 1,2,3-triazolobenzodiazepines 
derivatives in cancer studies. The cellular potency profile of 
18 and 20 also closely correlated with positive control JQ-1.  
 
 
We used RNA-seq to compare the effect of 20 and JQ-1 on 
global gene expression in THP-1 leukemia cells. These 
experiments revealed that the effect on gene expression 
between these two compounds is highly correlated for both up 
and down regulated genes (Figure 3A). In particular, BRD4-
dependent oncogene c-MYC demonstrated robust 
downregulation on treatment with 20 (Figure 3B) whilst 
HEXIM1 levels were upregulated.
26
  Similar effects on c-MYC 
and BCL-2 downregulation were observed for JQ-1, 18, 20 
and non-diazepine BET inhibitor IBET-151 in MV4-11 cells 
(data not shown, see electronic supporting information for full 
data). 
 
 
 
 
 
In summary, we developed a novel series of 5H-
benzo[f][1,2,3]triazolo[1,5-d][1,4]diazepines. Structure-
activity relationship studies and crystal structure-guided 
optimization led to the development of analogs with single-
digit nanomolar activity. Compound 20, showed good BET 
bromodomain selectivity and potent activity against a number 
of BRD4-dependant leukaemia cell lines and caused down-
regulation of oncogene MYC. Taken together these data show 
that the benzodiazepine scaffold is an useful framework on 
which to base BET bromodomain inhibtors. 
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Table 2. Treatment of various cancer cell lines with 18, 20 
or JQ-1 for 72 h. Cell viability measure by Cell-TiterGlo
TM
 
Figure 3. A. GENAS plot comparing effects of 20 and JQ-1 
on THP-1 cells. B. Identity of 10 highest up and down 
regulated genes by 20 and JQ-1. 
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